AERI

ANALYST NOTE: AERI (Aerie Pharmaceuticals, Inc.) Date: 2026-06-13 Current Price: $15.25

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR at Breakout: — ATR Current: 0.2% (Sub-threshold) Pivot Strength: — Cap Bucket: Small Sector: — Industry: —

Analysis:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

At this date, there is no named secular thesis driving AERI. The investment case is strictly tactical and setup-led. The conviction must be derived entirely from the quality of the technical setup (which is currently undefined due to missing data) and the underlying business fundamentals. No macro or thematic exposure (e.g., "aging population," "biotech innovation cycle") is explicitly attached to this name in the current evidence base. The analysis must remain agnostic to external market narratives and focus solely on the company's operational execution and the specific setup readiness, which is currently indeterminate.

3. Business Overview

Company Profile: Aerie Pharmaceuticals, Inc. operates as a pharmaceutical enterprise focused on the discovery, development, and commercialization of ophthalmic treatments for the U.S. market.

Commercial Portfolio: The company's commercialized portfolio features Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure (IOP) for patients with open-angle glaucoma or ocular hypertension.

Pipeline & Development: The company is advancing AR-15512 to address the symptoms and signs of dry eye. Additionally, the pipeline includes AR-1105 and AR-14034 SR, which are sustained-release implants targeting various retinal diseases. The company also engages in a collaborative research, development, and licensing agreement with DSM Biomedical.

Financial Performance & Guidance (Historical Context): While the current date is 2026, the only available financial evidence dates to the second quarter of 2022.

• Revenue Growth: In Q2 2022, combined Rocklatan and Rhopressa net revenues totaled $33.3 million, representing a 23% increase over the second quarter of 2021.
• Guidance (2022): Management reiterated guidance for 2022 net product revenues between $130 million and $140 million.
• Cash Flow Expectations: Management stated an expectation to achieve cash flow breakeven during 2024.
• Clinical Milestones: As of the 2022 earnings call, COMET-2 and COMET-3 registrational studies were enrolling, with COMET-4 scheduled for Q4 2022. Management indicated that, assuming clinical success, an NDA filing was planned for 2024.

Market Context: Management noted the prescription market for dry eye is approximately $1.6 billion, expanding to roughly $3 billion when including artificial eye drops.

4. Archetype and Conviction

Archetype Candidate: Growth Leader Fit Analysis: The name is categorized as a "Growth Leader" based on its historical trajectory of revenue expansion in its glaucoma franchise and the potential for new product launches in the dry eye and retinal markets. However, the "Growth Leader" classification is based on the 2022 evidence of 23% revenue growth and the strategic pipeline.

Conviction Stack:

• Thesis Strength: Low. No named secular thesis exists; the case is purely tactical.
• Evidence Quality: Mixed. The evidence base is heavily skewed toward 2022 data. There is a significant gap in evidence regarding the company's actual financial status, clinical trial results, or revenue performance in the years between 2022 and the current date of 2026. The 2022 guidance for 2024 breakeven is a historical management expectation, not a confirmed current status.
• Structural Quality: Unknown. The structural setup is missing. The sub-threshold ATR (0.2%) suggests a lack of volatility, which is often a precursor to a breakout but does not confirm one.
• Rerating Potential: Dependent on the resolution of the missing evidence. If the company has successfully achieved the 2024 breakeven target and launched new products, the rerating potential is high. If the 2024 target was missed, the rerating potential is low.

Valuation Context: No valuation metrics (P/E, P/S, EV/EBITDA) are available in the evidence base for 2026. The current price of $15.25 cannot be contextualized against historical multiples or intrinsic value without further financial data.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate the Case:

• Fundamental: Evidence that the company failed to achieve cash flow breakeven by 2024 or missed the 2024 NDA filing targets for AR-15512.
• Operational: Significant delays in the COMET studies or negative safety data from the sustained-release implants.

What Would Strengthen the Case:

• Structural: A confirmed breakout above a defined resistance level with volume expansion.
• Fundamental: Confirmation of successful NDA filings and subsequent product launches in the dry eye or retinal markets.
• Financial: Evidence of sustained revenue growth post-2022, exceeding the 2022 guidance trajectory.

Gaps in the Evidence Base:

• Critical Missing Data: There is a complete absence of financial or operational data between the 2022 earnings call and the current date of 2026-06-13.
• Current Financials: No current revenue, expense, or cash flow figures to verify the 2024 breakeven expectation.
• Clinical Status: No update on the status of the COMET studies or the NDA filing status for AR-15512.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: 1) Revenue growth of 23% in Q2 2022 with $33.3M in combined net revenues; 2) Management expectation of cash flow breakeven in 2024; 3) Sub-threshold ATR of 0.2% indicating low volatility. Key risks: 1) Complete absence of evidence for the period 2023-2026; 2) Potential failure to meet 2024 breakeven or NDA filing targets; 3) Lack of structural setup data prevents technical confirmation. Sizing hint: Position size should be minimal or zero until structural setup and fundamental evidence gaps are filled. Expected path: The situation will likely develop as management provides updates on clinical trial results and financial performance, potentially leading to a structural setup formation if volatility increases. Expected horizon: Indeterminate until new evidence is released.